| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $437,650 | 2 | 100 |
| Echelard Yann | director | 0 | $0 | 1 | $162,850 | $-162,850 |
| Charney Laurence N | director | 0 | $0 | 1 | $274,800 | $-274,800 |
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell …
Over the last 12 months, insiders at TG Therapeutics, Inc. have bought $0 and sold $437,650 worth of TG Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TG Therapeutics, Inc. have bought $1.11M and sold $2.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $1.01M was made by WEISS MICHAEL S (CEO and President) on 2023‑08‑11.
| 2026-09-10 | Sale | Charney Laurence N | director | 5,000 0.0035% | $54.96 | $274,800 | -0.13% | |
| 2025-11-24 | Sale | Echelard Yann | director | 5,000 0.0032% | $32.57 | $162,850 | +23.18% | |
| 2025-09-11 | Sale | Lonial Sagar | director | 20,852 0.0131% | $32.24 | $672,268 | +5.42% | |
| 2025-06-13 | Sale | Echelard Yann | director | 10,000 0.0065% | $36.94 | $369,400 | -10.09% | |
| 2025-01-06 | Sale | Power Sean A | CFO | 10,021 0.0065% | $28.53 | $285,939 | +21.75% | |
| 2025-01-03 | Sale | Power Sean A | CFO | 11,337 0.0073% | $30.29 | $343,443 | +13.61% | |
| 2024-11-11 | Sale | Charney Laurence N | director | 25,000 0.0157% | $30.20 | $754,875 | +12.39% | |
| 2024-11-11 | Sale | Lonial Sagar | director | 5,000 0.0032% | $30.44 | $152,200 | +12.39% | |
| 2024-11-05 | Sale | Echelard Yann | director | 20,000 0.0131% | $24.48 | $489,600 | +33.60% | |
| 2024-06-20 | Sale | Lonial Sagar | director | 16,348 0.011% | $16.87 | $275,791 | +81.36% | |
| 2024-06-17 | Sale | Lonial Sagar | director | 9,585 0.0063% | $16.39 | $157,098 | +85.40% | |
| 2024-03-13 | Sale | Lonial Sagar | director | 5,000 0.0033% | $15.94 | $79,675 | +47.23% | |
| 2024-03-12 | Sale | Charney Laurence N | director | 22,000 0.0144% | $15.97 | $351,340 | +45.96% | |
| 2024-01-05 | Sale | Charney Laurence N | director | 17,500 0.0112% | $19.03 | $333,025 | -2.29% | |
| 2024-01-03 | Sale | Power Sean A | CFO | 47,867 0.0318% | $16.91 | $809,431 | +13.54% | |
| 2023-08-11 | WEISS MICHAEL S | CEO and President | 100,000 0.0669% | $10.13 | $1.01M | +51.09% | ||
| 2023-06-23 | Sale | Lonial Sagar | director | 34,854 0.0246% | $23.37 | $814,538 | -36.08% | |
| 2023-06-02 | Sale | Power Sean A | Chief Financial Officer | 73,647 0.0528% | $26.70 | $1.97M | -43.20% | |
| 2023-01-06 | Echelard Yann | director | 9,000 0.0063% | $10.64 | $95,760 | +45.42% | ||
| 2023-01-04 | Sale | Charney Laurence N | director | 30,000 0.0221% | $11.10 | $333,000 | +44.40% |
| Echelard Yann | director | 223816 0.1462% | $13.6M | 1 | 4 | +45.42% |
| WEISS MICHAEL S | CEO and President | 12073021 7.8866% | $733.44M | 6 | 3 | +67.94% |
| LFB Biotechnologies S.A.S.U. | 10 percent owner | 5114855 3.3412% | $310.73M | 1 | 0 | +3.39% |
| ROSENWALD LINDSAY A MD | 10 percent owner | 2649321 1.7306% | $160.95M | 59 | 0 | |
| WEISER MICHAEL | director | 2213338 1.4458% | $134.46M | 1 | 0 | |
| Power Sean A | CFO | 660611 0.4315% | $40.13M | 2 | 23 | |
| Herskowitz Neil | director | 51265 0.0335% | $3.11M | 8 | 0 | +168.29% |
| ABEL DOUGLAS | President and CEO | 30000 0.0196% | $1.82M | 8 | 0 |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$98,300,471 | 40 | 0.27% | $14.91B |
| Increased Positions | 196 | +50% | 12M | +12.11% |
| Decreased Positions | 170 | -43.37% | 8M | -7.63% |
| New Positions | 63 | New | 3M | New |
| Sold Out Positions | 54 | Sold Out | 2M | Sold Out |
| Total Postitions | 418 | +6.63% | 104M | +4.48% |
| Blackrock, Inc. | $623,676.00 | 13.4% | 21.3M | -512,881 | -2.35% | 2025-09-30 |
| Vanguard Group Inc | $454,464.00 | 9.76% | 15.52M | -288,018 | -1.82% | 2025-09-30 |
| State Street Corp | $237,186.00 | 5.1% | 8.1M | +482,381 | +6.33% | 2025-09-30 |
| Clearbridge Investments, Llc | $135,990.00 | 2.92% | 4.64M | +2M | +52.15% | 2025-09-30 |
| Soleus Capital Management, L.P. | $112,574.00 | 2.42% | 3.84M | +2M | +71.34% | 2025-09-30 |
| Geode Capital Management, Llc | $100,838.00 | 2.17% | 3.44M | -46,538 | -1.33% | 2025-09-30 |
| Pictet Asset Management Holding Sa | $47,128.00 | 1.01% | 1.61M | -297,940 | -15.62% | 2025-09-30 |
| Hood River Capital Management Llc | $45,466.00 | 0.98% | 1.55M | -14,718 | -0.94% | 2025-09-30 |
| Goldman Sachs Group Inc | $44,487.00 | 0.96% | 1.52M | -50,536 | -3.22% | 2025-09-30 |
| Northern Trust Corp | $43,971.00 | 0.94% | 1.5M | -33,990 | -2.21% | 2025-09-30 |